Allergan, Ironwood Seek To Divide And Conquer IBS With New Linzess Formulations

Allergan and Ironwood Pharmaceuticals are beefing up the blockbuster potential of their IBS drug Linzess with two new formulations that target different disease populations showing promising Phase II data. Further Phase IIb and III trials are now in the offing.